Evaluating surgery with or without additional radiotherapy for intermediate risk cervical cancer
Official title: An International Randomised Trial of Radical Surgery Followed by Adjuvant (Chemo)Radiation Versus no Further Treatment in Patients With Early-stage, Intermediate-risk Cervical Cancer Patients
Run by The Central and Eastern European Gynecologic Oncology Group · NCT04989647 · Data updated 2026-11-12
This study is testing if adding radiation therapy after surgery helps people with intermediate risk cervical cancer live longer without their cancer coming back.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 85 Years |
| Sex | Women only |
| Enrollment | 514 (estimated) |
| Sponsor | The Central and Eastern European Gynecologic Oncology Group Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Prague) |
| Status | Recruiting |
| Started | June 10, 2022 |
| Main results expected | December 2029 |
| Study ends | December 2032 |
| Registry record updated | September 7, 2023 |
| Trial ID | NCT04989647 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with pathologically confirmed invasive cervical cancer classified as FIGO IB1-IIA and exhibiting specific tumor-related risk factors.
✕Probably not a fit
Patients with adenosquamous cancer or unusual types of adenocarcinoma, as well as those with evidence of lymph node involvement or distant metastases, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial aims to determine whether adjuvant (chemo)radiotherapy improves disease-free survival in patients with intermediate risk cervical cancer after radical surgery. A total of 514 patients will be enrolled and randomly assigned to receive either no additional treatment or adjuvant radiotherapy following surgery. The study will assess the primary endpoint of disease-free survival using a Cox proportional hazards model, with a focus on providing high-quality evidence regarding the effectiveness of adjuvant treatment in this patient population.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the role of adjuvant therapy, potentially improving outcomes for patients with intermediate risk cervical cancer.
How similar studies have gone: Previous studies have shown mixed results regarding the role of adjuvant treatment in similar patient populations, making this trial a significant effort to clarify the issue.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically confirmed invasive cervical cancer * FIGO IB1-IIA * Squamous cell cancer or HPV-related adenocarcinoma * Presence of tumour-related risk factors as follows: 1. tumour ≥4 cm OR 2. tumour\>2 cm \<4 cm AND lymphovascular space invasion OR 3. tumour \>2 cm \<4 cm AND tumour free distance \<3 mm OR 4. tumour \>2 cm \<4 cm AND deep stromal invasion (\>2/3) * No evidence of suspicious pelvic lymph nodes or distant metastases on imaging (by radiological subjective assessment before surgery and negative pelvic LN on final pathology) * ECOG performance status 0-1 * Deemed suitable and fit for radical surgery followed by adjuvant radiotherapy * Negative pregnancy test (if applicable) * Negative HIV test (only performed in high-risk countries or patients who have moved from those countries within the past 10 years) Exclusion Criteria: * Adenosquamous cancer or adenocarcinoma unusual type (non-HPV related - such as: mucinous, clear cell, mesonephric) or other rare tumour types (those not listed in the inclusion criteria) * Inconclusive primary site of disease * Unequivocally positive lymph node by imaging (by radiological subjective assessment) * FIGO \<IB1 / \>IIA * Previous pelvic malignancy * History of second primary cancer outside pelvis if ≤ 3 years complete clinical remission (CCR) * Previous pelvic radiotherapy * Neoadjuvant chemotherapy prior surgical treatment * Low likelihood of patient compliance to the follow-up
Where it's running
-
General University Hospital in Prague
Prague, Czechia Recruiting
Study contacts
- Principal investigator: David Cibula, prof. — General University Hospital in Prague, Czech Republic
- Study coordinator: Martina Borcinova, PhD
- Email: martina.borcinova@cervantes-trial.com
- Phone: +420224969298
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cervical screening and care options for women living with HIV who test positive for high-risk HPV
This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.
-
Hydrogel spacer to protect the rectum during cervical cancer radiotherapy
This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.
-
How cinema sessions during chemotherapy might help cervical cancer patients
We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.